A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine.

Trial Profile

A phase II study of nab-Paclitaxel therapy in reductive dose for patients with advanced/recurrent gastric cancer after prior treatments including fluoropyrimidine.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 11 Jan 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Adenocarcinoma; Gastric cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jan 2017 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
    • 28 Jan 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
    • 25 Dec 2014 Planned initiation date changed from 1 Jan 2014 to 4 Apr 2014 as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top